Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

GV-150526A in development for stroke

April 5, 1996

Novel ETA/ETB antagonist reduces brain injury

April 5, 1996

SYM-2206 for seizure prevention

April 5, 1996

New anthranilide in phase I at Glaxo Wellcome

April 5, 1996

L-745870: D4 antagonist for schizophrenia

April 5, 1996

New antipsychotic drug in phase I at P&U

April 5, 1996

Pierre Fabre reports hypocholesterolemic organosilanes

April 5, 1996

Vitronectin antagonist from Merck & Co. inhibits bone resorption

April 5, 1996

New telomerase inhibitor from Geron

April 5, 1996

PD-145709: New tyrosine kinase inhibitor from Warner-Lambert

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...